| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
BRIEF REPORT |
Department of Internal Medicine, University of Pisa, 56126 Pisa, Italy
Address all correspondence and requests for reprints to: Fabio Monzani, M.D., Department of Internal Medicine, University of Pisa, via Roma 67, 56126 Pisa, Italy. E-mail: fmonzani{at}med.unipi.it.
Aim: We evaluated endothelial-dependent vasodilation after administration of recombinant human TSH (rhTSH) in patients monitored for differentiated thyroid carcinoma. The role of inflammation and oxidative stress was also assessed.
Protocol: Twenty-four patients (21 women, mean age 40.5 ± 9.2 yr) received rhTSH (0.9 mg daily) on 2 consecutive days. At baseline and the day after the second rhTSH injection, endothelium-dependent vasodilation as flow-mediated dilation (FMD, induced by 5 min of forearm ischemia) and endothelium-independent vasodilation (glyceril trinitrate 25 µg, sublingual) were evaluated by high-resolution ultrasound in the brachial artery. At each experimental time, blood was drawn for the evaluation of thyroglobulin, TSH, free T3, free T4, as well as IL-6, C reactive protein, TNF
, lipoperoxides, and ferric reducing antioxidant power levels as markers of inflammation and oxidative stress.
Results: At baseline, patients serum TSH values were below the normal range [0.12 mIU/liter (range 0.010.30)] in the face of normal free T4 and free T3 levels; FMD (8.9 ± 3.4 vs. 9.2 ± 3.1%, respectively) and response to glyceril trinitrate (11.0 ± 4.3 vs. 10.8 ± 4.7%, respectively) were similar in patients and controls. All the patients had serum thyroglobulin value less than 1 ng/ml, suggesting the absence of cancer recurrences. Besides the expected elevation of serum TSH, rhTSH induced a significant impairment of FMD (7.4 ± 3.0 vs. 8.9 ± 3.4%; P < 0.01) along with a significant elevation of blood IL-6 (P = 0.01), TNF
(P < 0.001), and lipoperoxide levels (P = 0.01), as well as a reduction of ferric reducing antioxidant power (P = 0.01).
Conclusions: rhTSH administration acutely impaired endothelium-dependent vasodilation, possibly through the induction of low-grade inflammation and reduced nitric oxide availability by oxidative stress.
This article has been cited by other articles:
![]() |
T. T. Antunes, A. Gagnon, M. L. Langille, and A. Sorisky Thyroid-Stimulating Hormone Induces Interleukin-6 Release from Human Adipocytes through Activation of the Nuclear Factor-{kappa}B Pathway Endocrinology, June 1, 2008; 149(6): 3062 - 3066. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Napoli, B. Biondi, V. Guardasole, C. D'Anna, A. De Sena, C. Pirozzi, D. Terracciano, C. Mazzarella, M. Matarazzo, and L. Sacca Enhancement of Vascular Endothelial Function by Recombinant Human Thyrotropin J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1959 - 1963. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O. Asvold, T. Bjoro, T. I. L. Nilsen, D. Gunnell, and L. J. Vatten Thyrotropin Levels and Risk of Fatal Coronary Heart Disease: The HUNT Study Arch Intern Med, April 28, 2008; 168(8): 855 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dardano and F. Monzani Recombinant human TSH acutely impairs endothelium-dependent vasodilation Eur. J. Endocrinol., September 1, 2007; 157(3): 367 - 367. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |